영진약품

003520KOSPI의약품 제조업

34.5 / 100

Reference Date: 2026-04-13

Financial Score8.0 / 40

News Sentiment12.5 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Slightly down 3.1% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Youngjin Pharmaceutical, a core subsidiary of KT&G Group, has built trust through awards such as the Presidential Award and focuses on enhancing national health and the pharmaceutical industry. In 2025, it achieved sales of 2.543 trillion KRW and an operating profit of 34 billion KRW, strengthening its domestic market position and diversifying exports globally. It is driving growth through R&D investment and ESG management to solidify its position as a global pharmaceutical company.

Number of Employees

626people

Average Salary

69.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 14.804.0Point

PBR

3.51Industry Average 1.040.0Point

3.4x industry avg (risky)

ROE

-0.25Industry Average 4.420.0Point

Well below industry avg

Debt Ratio

79.18Industry Average 11.980.0Point

6.6x industry avg (risky)

Trend 2023~20254.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲4.1% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲59.5% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -1.1% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 0Neutral 1Negative 0Average Sentiment Score 50

Neutral
또 ‘롤러코스피’ 올까…증시 조정 경계심에 공매도 대기자금 ‘최대...
증시 조정 경계심에 따른 공매도 대기자금 증가에 대한 뉴스로, 영진약품에 대한 직접적인 언급은 없습니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (8%, downtrend)

Current 1,755Won52-week high 2,36052-week low 1,700

1-month return2.0Point

1m -3.09% (slight drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-20
Neutral정기주주총회결과2026-03-20